323 related articles for article (PubMed ID: 19801220)
21. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment.
Cook GJ; Azad GK; Goh V
J Nucl Med; 2016 Feb; 57 Suppl 1():27S-33S. PubMed ID: 26834098
[TBL] [Abstract][Full Text] [Related]
22. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET.
Huyge V; Garcia C; Vanderstappen A; Alexiou J; Gil T; Flamen P
Clin Nucl Med; 2009 Jul; 34(7):417-20. PubMed ID: 19542943
[TBL] [Abstract][Full Text] [Related]
23. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
24. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.
Grant FD; Fahey FH; Packard AB; Davis RT; Alavi A; Treves ST
J Nucl Med; 2008 Jan; 49(1):68-78. PubMed ID: 18077529
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: role of SPECT and PET in imaging bone metastases.
Beheshti M; Langsteger W; Fogelman I
Semin Nucl Med; 2009 Nov; 39(6):396-407. PubMed ID: 19801219
[TBL] [Abstract][Full Text] [Related]
26. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.
Uematsu T; Yuen S; Yukisawa S; Aramaki T; Morimoto N; Endo M; Furukawa H; Uchida Y; Watanabe J
AJR Am J Roentgenol; 2005 Apr; 184(4):1266-73. PubMed ID: 15788608
[TBL] [Abstract][Full Text] [Related]
27. (18)F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with (18)F-FDG and bioluminescence imaging.
Kang WJ; Song EH; Park JY; Park YJ; Cho A; Song HT
Nucl Med Biol; 2015 Sep; 42(9):728-33. PubMed ID: 26068116
[TBL] [Abstract][Full Text] [Related]
28. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
29. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Bone Lesions with
van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
[TBL] [Abstract][Full Text] [Related]
31. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
32. The Potential of Radiolabeled Bisphosphonates in SPECT and PET for Bone Imaging.
Ashhar Z; Ahmad Fadzil MF; Hassan H; Othman MF; Md Hassan MB; Chun Vui VY; Guat Choo C; Yusof NA
Curr Med Imaging; 2024; 20(1):e15734056270935. PubMed ID: 38874043
[TBL] [Abstract][Full Text] [Related]
33.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
34. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
[TBL] [Abstract][Full Text] [Related]
35. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Anticancer Res; 2005; 25(6C):4439-44. PubMed ID: 16334123
[TBL] [Abstract][Full Text] [Related]
36. Fasting Enhances the Contrast of Bone Metastatic Lesions in
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238
[No Abstract] [Full Text] [Related]
37. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor.
Tateishi U; Morita S; Taguri M; Shizukuishi K; Minamimoto R; Kawaguchi M; Murano T; Terauchi T; Inoue T; Kim EE
Ann Nucl Med; 2010 Aug; 24(7):523-31. PubMed ID: 20559896
[TBL] [Abstract][Full Text] [Related]
38. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities.
Even-Sapir E
J Nucl Med; 2005 Aug; 46(8):1356-67. PubMed ID: 16085595
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
[TBL] [Abstract][Full Text] [Related]
40. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
